NASDAQ:CERS Cerus - CERS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. $3.01 -0.11 (-3.53%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.00▼$3.1450-Day Range$2.72▼$4.2252-Week Range$2.53▼$6.00Volume1.03 million shsAverage Volume1.69 million shsMarket Capitalization$534.03 millionP/E RatioN/ADividend YieldN/APrice Target$4.88 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cerus MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside62.0% Upside$4.88 Price TargetShort InterestBearish3.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 2 Articles This WeekInsider TradingSelling Shares$48,875 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.21) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector783rd out of 1,055 stocksSurgical & Medical Instruments Industry78th out of 106 stocks 3.2 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.88, Cerus has a forecasted upside of 62.0% from its current price of $3.01.Amount of Analyst CoverageCerus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.54% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Cerus has recently increased by 11.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 1.7 News and Social Media Coverage News SentimentCerus has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cerus this week, compared to 2 articles on an average week.Search Interest15 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,875.00 in company stock.Percentage Held by InsidersOnly 7.33% of the stock of Cerus is held by insiders.Percentage Held by Institutions82.47% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.21) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerus (NASDAQ:CERS) StockCerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.Read More Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address CERS Stock News HeadlinesJanuary 23, 2023 | americanbankingnews.comBTIG Research Lowers Cerus (NASDAQ:CERS) to NeutralJanuary 23, 2023 | americanbankingnews.comCerus (NASDAQ:CERS) Downgraded by BTIG ResearchJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 9, 2023 | finance.yahoo.comCerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business UpdateDecember 21, 2022 | finance.yahoo.comCerus Corporation's (NASDAQ:CERS) recent 9.2% pullback adds to one-year year losses, institutional owners may take drastic measuresNovember 21, 2022 | benzinga.comCerus's Return On Capital Employed OverviewNovember 9, 2022 | finance.yahoo.comCerus Third Quarter 2022 Earnings: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)November 3, 2022 | finance.yahoo.comCerus Corporation Announces Third Quarter Financial ResultsJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 2, 2022 | finance.yahoo.comCerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized CryoprecipitateNovember 1, 2022 | finance.yahoo.comCerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day StorageOctober 20, 2022 | finance.yahoo.comCerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022October 2, 2022 | fool.comCerus (NASDAQ: CERS)September 29, 2022 | seekingalpha.comCerus Stock: Technical Support Fades, Investment Case Weakens (NASDAQ:CERS) - Seeking AlphaSeptember 29, 2022 | nasdaq.comDoes Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?September 26, 2022 | benzinga.comCerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting - Cerus (NASDAQ:CERS) - BenzingaSeptember 26, 2022 | finance.yahoo.comCerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual MeetingSeptember 21, 2022 | finance.yahoo.comAfter Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)September 19, 2022 | finance.yahoo.comCerus Corporation (CERS)September 14, 2022 | finance.yahoo.comInvestors in Cerus (NASDAQ:CERS) have made a decent return of 59% over the past five years - Yahoo FinanceSeptember 14, 2022 | finance.yahoo.comInvestors in Cerus (NASDAQ:CERS) have made a decent return of 59% over the past five yearsSeptember 13, 2022 | nasdaq.comZimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains? - NasdaqSeptember 11, 2022 | reuters.comCERS.O - Cerus Corporation | Stock Price & Latest News | ReutersSeptember 10, 2022 | reuters.comCERS.OQ - Cerus Corporation | Stock Price & Latest News | ReutersSeptember 6, 2022 | streetinsider.comInstil Bio Announces Appointment of Tim Moore as Chief Operating Officer - StreetInsider.comSeptember 1, 2022 | globenewswire.comBlood Purification Devices Market Size Will Achieve USD - GlobeNewswireAugust 29, 2022 | nasdaq.comDown 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address CERS Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)2/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees631Year Founded1991Price Target and Rating Average Stock Price Forecast$4.88 High Stock Price Forecast$6.00 Low Stock Price Forecast$3.75 Forecasted Upside/Downside+62.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,380,000.00 Net Margins-24.24% Pretax Margin-24.09% Return on Equity-48.32% Return on Assets-17.18% Debt Debt-to-Equity Ratio0.37 Current Ratio1.73 Quick Ratio1.44 Sales & Book Value Annual Sales$130.86 million Price / Sales4.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.02Miscellaneous Outstanding Shares177,420,000Free Float164,416,000Market Cap$534.03 million OptionableOptionable Beta1.09 Social Links Key ExecutivesObi GreenmanPresident, Chief Executive Officer & DirectorVivek K. JayaramanChief Operating OfficerKevin Dennis GreenChief Financial Officer & Vice President-FinanceLaurence M. CorashChief Scientific OfficerCarol M. MooreSenior VP-Regulatory Affairs, Quality & ClinicalKey CompetitorsAnika TherapeuticsNASDAQ:ANIKOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDAtrionNASDAQ:ATRICardiovascular SystemsNASDAQ:CSIIView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 160,739 shares on 1/30/2023Ownership: 4.042%New York State Common Retirement FundSold 19,110 shares on 1/30/2023Ownership: 0.061%Versor Investments LPBought 13,300 shares on 1/30/2023Ownership: 0.007%Rice Hall James & Associates LLCSold 17,570 shares on 1/27/2023Ownership: 0.313%Joel Isaacson & Co. LLCBought 63,000 shares on 1/27/2023Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions CERS Stock - Frequently Asked Questions Should I buy or sell Cerus stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares. View CERS analyst ratings or view top-rated stocks. What is Cerus' stock price forecast for 2023? 3 Wall Street analysts have issued 12 month target prices for Cerus' shares. Their CERS share price forecasts range from $3.75 to $6.00. On average, they predict the company's stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. How have CERS shares performed in 2023? Cerus' stock was trading at $3.65 on January 1st, 2023. Since then, CERS shares have decreased by 17.5% and is now trading at $3.01. View the best growth stocks for 2023 here. Are investors shorting Cerus? Cerus saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,280,000 shares, an increase of 11.7% from the December 31st total of 5,620,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is presently 4.8 days. View Cerus' Short Interest. When is Cerus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023. View our CERS earnings forecast. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The biotechnology company earned $39.57 million during the quarter, compared to analysts' expectations of $39 million. Cerus had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 48.32%. What guidance has Cerus issued on next quarter's earnings? Cerus issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$162.00 million, compared to the consensus revenue estimate of $173.50 million. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA). What is Cerus' stock symbol? Cerus trades on the NASDAQ under the ticker symbol "CERS." Who are Cerus' major shareholders? Cerus' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (8.94%), Sumitomo Mitsui Trust Holdings Inc. (4.04%), Assenagon Asset Management S.A. (1.41%), Stephens Inc. AR (0.36%), Rice Hall James & Associates LLC (0.31%) and Exchange Traded Concepts LLC (0.14%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cerus' stock price today? One share of CERS stock can currently be purchased for approximately $3.01. How much money does Cerus make? Cerus (NASDAQ:CERS) has a market capitalization of $534.03 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. How many employees does Cerus have? The company employs 631 workers across the globe. How can I contact Cerus? Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001. This page (NASDAQ:CERS) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.